Dr. Wyatt has disclosed that he has a consulting or advisory role with Sanofi. Dr. Youngren has disclosed that he receives research funding from Zenith Epigenetics. Dr. Beer has disclosed that he has stock or other ownership interests with Salarius Pharmaceuticals; has a consulting or advisory role with Abbvie, AstraZeneca, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Janssen Biotech, Astellas, Bayer, Boehringer Ingelheim, Janssen Oncology, Janssen Research & Development, Johnson & Johnson, Janssen Japan, F. Hoffmann La Roche, Merck, and Pfizer; and receives grant or research support from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences. Dr. Feng has disclosed that he has a leadership role at PFS Genomics; has served as a consultant for Clovis, Bayer, Medivation/Astellas, GenomeDx, Celgene, Dendreon, EMD Serono, Janssen Oncology, Ferring, and sanofi-aventis; receives grant or research support from Medivation/Astellas, Varian Medical Systems, and Celgene; and helped develop a molecular signature to predict radiation resistance in breast cancer, which was patented by the University of Michigan, and is in the process of being licensed to PFS Genomics. Dr. Small has disclosed that he has stock or other ownership interests with Fortis Therapeutics and Harpoon Therapeutics; receives honoraria from Janssen-Cilag; has a consulting and advisory role with Fortis Therapeutics, Gilead Sciences, and Valeant Pharmaceuticals International; and receives grant or research support from Janssen. Dr. Alumkal has disclosed that he has a consulting or advisory role with Astellas Pharma, Bayer, and Janssen Biotech; and that he receives research funding from Aragon, Astellas, Gilead Sciences, Novartis, and Zenith. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
Lorente D, Mateo J, Perez-Lopez R et al.. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015;16:e279–292.
Farmer H, McCabe N, Lord CJ et al.. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–921.
Castro E, Mateo J, Olmos D et al.. Targeting DNA repair: the role of PARP inhibition in the treatment of castration-resistant prostate cancer. Cancer J 2016;22:353–356.
McCabe N, Turner NC, Lord CJ et al.. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-8115.
Hussain M, Carducci MA, Slovin S et al.. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014;32:904–912.
Hussain M, Daignault S, Twardowski P et al.. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol 2018;36:991–999.
Mateo J, Carreira S, Sandhu S et al.. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373:1697–1708.
Tao DL, Bailey S, Beer TM et al.. Molecular testing in patients with castration-resistant prostate cancer and its impact on clinical decision making [published online June 28, 2017]. JCO Precis Oncol, doi: 10.1200/PO.16.00067
Liu X, Wu C, Li C et al.. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat 2016;37:235–241.
Quigley D, Alumkal JJ, Wyatt AW et al.. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov 2017;7:999–1005.
Christie EL, Fereday S, Doig K et al.. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 2017;35:1274-1280.
Wyatt AW, Annala M, Aggarwal R et al.. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer [published online December 1, 2017]. J Natl Cancer Inst, doi: 10.1093/jnci/djx118
Goodall J, Mateo J, Yuan W et al.. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 2017;7:1006–1017.